Melsi – an anti-inflammatory drug made by Astrapharm

Patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis often report complaints of pain and stiffness in the joints of the spine, which significantly impair their quality of life.

To alleviate the condition of such patients, the pharmaceutical company Astrapharm produces non-steroidal anti-inflammatory and anti-rheumatic drug Melsi with the active ingredient meloxicam.

Melsi is a non-steroidal anti-inflammatory drug (NSAID) structurally related to the enolic acid class. By inhibiting the biosynthesis of prostaglandins, which are mediators of inflammation, the drug shows the following effects:

• anti-inflammatory;
• analgetic;
• antipyretic

The advantage of Melsi is a safety mechanism of action compared to other NSAIDs: the drug significantly reduces the risk of gastrointestinal complications. This is due to selective inhibition of cyclooxygenase-2 (COX-2) – the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins.

Melsi comes in tablets, that contain 7,5 or 15 mg of meloxicam №20, and in vials 10 mg/ml 1,5 ml №5.

The drug is dispensed on prescription only.

Astrapharm – the art of helping people!